Wafermine: the world’s first patented sublingual racemic ketamine wafer for pain and depression

iX Biopharma is transforming approved drugs such as ketamine into novel therapies using its wafer-based sublingual technology, to develop therapies for pain, depression and more.

Go to the profile of ix Biopharma
Sep 12, 2019
0
0
Page of
Go to the profile of ix Biopharma

ix Biopharma

iX Biopharma Ltd is a Singapore public-listed late-stage specialty pharmaceutical company with a keen focus on the development and commercialisation of innovative therapies that improve the quality of life for those suffering from pain and other health conditions. Our Company operates a fully integrated business model, with its fully-licensed facilities in Melbourne, Australia. Our Company is able to undertake drug development and formulation, laboratory testing, manufacturing and the supply of its products to consumers. Our Company has also developed a patented, fast-dissolving wafer formulation, WaferiX™; a multiple platform technology (matrix for drug carrier) that can deliver a vast number of drugs and other active ingredients approved by regulatory bodies. This administration allows faster delivery and reduction in loss of drugs due to hepatic and gastrointestinal metabolism, hence improving the bioavailability of the drugs.

No comments yet.